Overview

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
In this study investigators will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the brain circuitry, function and local neurochemistry, and their correlation with neuropsychological function.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Efavirenz
Raltegravir Potassium